Rare Community Profiles: Wet Age-Related Macular Degeneration: Treatments Continue to Improve
source: shutterstock.com

Rare Community Profiles: Wet Age-Related Macular Degeneration: Treatments Continue to Improve

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Wet Age-Related Macular Degeneration: Treatments Continue to Improve
A Newly Initiated Phase 1 Study Will Evaluate AIV007 for Wet AMD, DME 
Skitterphoto / Pixabay

A Newly Initiated Phase 1 Study Will Evaluate AIV007 for Wet AMD, DME 

  In late May 2023, clinical-stage biotechnology company AiViva Biopharma Inc. ("AiViva") shared via news release that the company had launched a Phase 1 clinical study evaluating AIV007 for diabetic…

Continue Reading A Newly Initiated Phase 1 Study Will Evaluate AIV007 for Wet AMD, DME 
Vabysmo Shows Advantages Over Aflibercept in Wet AMD and Diabetic Macular Edema
source: pixabay.com

Vabysmo Shows Advantages Over Aflibercept in Wet AMD and Diabetic Macular Edema

An announcement from the drug company Genentech highlights the results of a recent study which demonstrated that the drug faricimab-svoa (marketed at Vabysmo) was able to dry retinal fluid more…

Continue Reading Vabysmo Shows Advantages Over Aflibercept in Wet AMD and Diabetic Macular Edema
Study: One Wet Age-Related Macular Degeneration Drug Appears Superior to the Other
https://unsplash.com/photos/In4XVKhYaiI

Study: One Wet Age-Related Macular Degeneration Drug Appears Superior to the Other

According to a story from hopkinsmedicine.org, a study evaluating data from 106 patients living with wet age-related macular degeneration found a significant disparity in outcomes when comparing patients that received…

Continue Reading Study: One Wet Age-Related Macular Degeneration Drug Appears Superior to the Other

Clinical Trial Results Show Wet Age-Related Macular Degeneration Patients May Need Less Frequent Treatment

Regeneron Pharmaceuticals has just announced the results from their Phase 2 trial of aflibercept. The trial aimed to compare an 8mg dose of the treatment to a 2mg dose, which…

Continue Reading Clinical Trial Results Show Wet Age-Related Macular Degeneration Patients May Need Less Frequent Treatment
Study Shows Some People with Wet Age-Related Macular Degeneration May Be Able to Stop Eye Injection Therapy
source: pixabay.com

Study Shows Some People with Wet Age-Related Macular Degeneration May Be Able to Stop Eye Injection Therapy

  According to a recent article, a pilot study shows that around 30% of patients with wet age-related macular degeneration might have the ability to stop their eye injection therapy…

Continue Reading Study Shows Some People with Wet Age-Related Macular Degeneration May Be Able to Stop Eye Injection Therapy